Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31050324 | 1.00 | ERN1 (0.52) | ERN1CYP2A6PTGDR2PTPN1PRKDC | |
| SCHEMBL13437720 | 0.84 | ERN1 (0.47) | ERN1CYP2A6PTGDR2PTPN1PRKDC | |
| SCHEMBL10018345 | 0.83 | ALDH1A1 (0.38) | ERN1ALDH1A1CCR2CA12CA9 | |
| SCHEMBL16960520 | 0.80 | ALDH1A1 (0.36) | ERN1ALDH1A1CCR2 | |
| SCHEMBL16952858 | 0.80 | ERN1 (0.38) | ERN1PTGDR2ALDH1A1CCR2LMNA | |
| SCHEMBL1145175 | 0.79 | ERN1 (0.47) | ERN1CYP2A6PTGDR2PTPN1PRKDC | |
| SCHEMBL21558279 | 0.79 | ERN1 (0.47) | ERN1CYP2A6PTGDR2PTPN1PRKDC | |
| SCHEMBL16528202 | 0.79 | ERN1 (0.47) | ERN1CYP2A6PTGDR2PTPN1PRKDC | |
| SCHEMBL7820970 | 0.76 | ERN1 (0.52) | ERN1PTPN1ALDH1A1CCR2 | |
| SCHEMBL29950830 | 0.76 | TYR (0.39) | ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| EP-2271624-B9 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-2271624-B1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-05-21 | — | — | EP | disclosed |
| US-8481569-B2 | Iminopyridine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-09 | — | — | US | disclosed |
| US-8283660-B2 | Small molecule semiconductor | XEROX CORPORATION (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283660-B2 | Small molecule semiconductor | XEROX CORPORATION (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283660-B2 | Small molecule semiconductor | XEROX CORPORATION (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | XEROX CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | XEROX CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | XEROX CORPORATION (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-17 | — | — | US | disclosed |
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2271624-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131245-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | WO | disclosed |
| US-7495007-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034464-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | ERN1 3832/4885CYP2A6 1930/4885PTGDR2 119/4885 |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | ERN1 974/4885CYP2A6 1581/4885PTGDR2 983/4885 |
| US-20110124876-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | ERN1 3832/4885CYP2A6 1930/4885PTGDR2 119/4885 |
| US-20110124875-A1 | IMINOPYRIDINE DERIVATIVES AND USES THEREOF | ADRA1D, ADRB1, ADRB2 | ERN1 3831/4885CYP2A6 2038/4885PTGDR2 131/4885 |
| US-20110124874-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | ERN1 3832/4885CYP2A6 1930/4885PTGDR2 119/4885 |
| US-20110039846-A1 | IMINOPYRIDINE DERIVATIVES AND USE THEREOF | ADRA1D, ADRB1, ADRB2 | ERN1 3832/4885CYP2A6 1930/4885PTGDR2 119/4885 |
| US-20120161109-A1 | SMALL MOLECULE SEMICONDUCTOR | SLC43A1, TST, SLC7A5 | ERN1 3101/4885CYP2A6 1578/4885PTGDR2 710/4885 |
| US-20090270393-A1 | Iminopyridine Derivatives and Use Thereof | ADRA1D, ADRB1, ADRB2 | ERN1 3832/4885CYP2A6 1930/4885PTGDR2 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.